AWM Investment Company Inc. trimmed its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 6.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 70,000 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the period. Loxo Oncology accounts for about 2.0% of AWM Investment Company Inc.’s investment portfolio, making the stock its 15th largest position. AWM Investment Company Inc.’s holdings in Loxo Oncology were worth $11,958,000 as of its most recent filing with the SEC.
Several other hedge funds also recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Loxo Oncology by 8.4% in the 3rd quarter. BlackRock Inc. now owns 2,271,428 shares of the biopharmaceutical company’s stock valued at $388,029,000 after acquiring an additional 176,264 shares in the last quarter. OppenheimerFunds Inc. raised its stake in shares of Loxo Oncology by 6.4% in the 2nd quarter. OppenheimerFunds Inc. now owns 1,115,675 shares of the biopharmaceutical company’s stock valued at $193,547,000 after acquiring an additional 66,794 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Loxo Oncology by 20.2% in the 3rd quarter. Alliancebernstein L.P. now owns 574,136 shares of the biopharmaceutical company’s stock valued at $98,080,000 after acquiring an additional 96,335 shares in the last quarter. Eagle Asset Management Inc. raised its stake in shares of Loxo Oncology by 494.4% in the 3rd quarter. Eagle Asset Management Inc. now owns 350,197 shares of the biopharmaceutical company’s stock valued at $59,824,000 after acquiring an additional 291,278 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Loxo Oncology by 14.0% in the 2nd quarter. Northern Trust Corp now owns 325,357 shares of the biopharmaceutical company’s stock valued at $56,442,000 after acquiring an additional 39,846 shares in the last quarter. 95.58% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Lori Anne Kunkel sold 5,000 shares of Loxo Oncology stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $170.37, for a total transaction of $851,850.00. Following the sale, the director now owns 5,000 shares of the company’s stock, valued at approximately $851,850. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jennifer Burstein sold 2,500 shares of Loxo Oncology stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $166.96, for a total value of $417,400.00. Following the sale, the vice president now directly owns 1,250 shares in the company, valued at approximately $208,700. The disclosure for this sale can be found here. Insiders have sold a total of 70,000 shares of company stock worth $11,618,850 in the last three months. 17.10% of the stock is owned by insiders.
Shares of NASDAQ LOXO opened at $150.18 on Friday. The company has a market capitalization of $4.52 billion, a price-to-earnings ratio of -28.28 and a beta of 2.26. Loxo Oncology Inc has a 12 month low of $71.45 and a 12 month high of $208.95.
Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.24). Loxo Oncology had a negative return on equity of 16.42% and a negative net margin of 43.49%. The business had revenue of $42.47 million during the quarter, compared to the consensus estimate of $38.55 million. During the same period in the prior year, the firm earned ($2.45) earnings per share. On average, equities analysts anticipate that Loxo Oncology Inc will post -2.34 earnings per share for the current year.
WARNING: This article was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.wkrb13.com/2018/11/23/loxo-oncology-inc-loxo-position-decreased-by-awm-investment-company-inc.html.
Loxo Oncology Profile
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Featured Story: How Do You Calculate Return on Equity (ROE)?
Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.